Real-world retrospective review of monotherapy following platinum-based chemotherapy for metastatic urothelial cancer.

ABSTRACT:

Objective

To compare estimated survival times of patients who had received maintenance monotherapy with gemcitabine (GEM), or an immuno-oncology (IO) drug (i.e., pembrolizumab or avelumab) or both therapies (one after the other) following platinum-based combination chemotherapy for metastatic urothelial carcinoma (UC) in a real-world setting.

Methods

For this retrospective study, we included consecutive patients with metastatic UC who had received first-line platinum-based chemotherapy followed by second-line treatment at our centre from March 2008 to June 2020.

Results

Of the 74 patients identified, 58 had received monotherapy as second line treatment, and 16 had received combination chemotherapy (i.e., non-monotherapy). The estimated median duration of survival was

SUBMITTER: Uchida H 

PROVIDER: S-EPMC10226317 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature